Home oxygen therapy for acute bronchiolitis

Michael Sarrell E*
Pediatric Ambulatory Center, General Health Services, Petach Tikva, Israel

Abstract

Objective: To investigate the utility of home oxygen treatment for acute bronchiolitis in infants.

Design: Prospective, randomized, intent-to-treat.

Setting: Pediatric tertiary, university-affiliated medical center.

Patients: 135 children aged < 12 months who presented to an urban primary pediatric clinic in 2009-2011 with RSV bronchiolitis and mild to moderate hypoxia.

Interventions: Random allocation to three groups: Inhaled hypertonic or bronchodilator + supplemental oxygen (2 l/min for 30 min 4 times daily) or bronchodilator only (control).

Main outcome measures: Number of emergency department visits and hospitalizations, number of lost days of daycare (infants) and work (parents), parental satisfaction, and changes in signs and symptoms.

Results: Background data were similar in all groups. Compared to the control group, oxygen-treated groups were characterized by a significantly shorter interval to normalization of respiratory rate and oxygen saturation ($p < 0.001$), significantly fewer hospital admissions ($p < 0.0001$), and emergency department referrals ($p < 0.001$), a significantly lower rate of chest infiltrates during follow-up ($p < 0.0001$), and fewer missed days of daycare and work ($p < 0.0001$). Rates of caregiver satisfaction were 88% and 78% in the oxygen-treated groups and 44% in the control group.

Conclusion: The administration of supplementary oxygen treatment at home in children aged < 12 months with RSV bronchiolitis is effective and safe, leading to a reduction in emergency department referrals and hospital admissions and an increase in caregiver satisfaction.

*Correspondence to: Michael Sarrell E, 7 Ha'Iris St. Moshav Gan Hayim 44910, Israel, Tel: +972-9-7409610, Cell: +972-544289279; Fax: +972-97403196; E-mail: michaelsar@clalit.org.il

Key words: oxygen, supplemental, bronchiolitis, RSV, epinephrine, infants, randomized control trial, nebulized inhalation

Received: June 06, 2019; Accepted: June 25, 2019; Published: June 28, 2019
investigators had shown that when supplemental $O_2$ was used the overall admission rates for bronchiolitis was reduced in the ED [14], and hospital readmission was avoided [15], furthermore, early discharge from ED and hospital was possible [16]. At present, bronchiolitis is the leading cause of hospitalization in infants [1,16]. In developed countries, 30 per 1000 children in the first year of life are hospitalized annually for bronchiolitis. Of children who develop bronchiolitis during the first 2 years of life, approximately 1 in 10 (3% of all infants in the USA) will be hospitalized [16,17]. Furthermore, in a substantial proportion of infants, the hospital stay until hypoxia improves may be prolonged [13], posing a further risk to these patients and increasing costs.

Prompted by these findings, we sought to determine if the number of ED referrals and hospitalizations of children with RSV bronchiolitis could be safely reduced by adding short-term home treatment with intermittent oxygen to the other treatments provided at the community primary care level.

Methods

Patients

The study population consisted of 135 infants aged less than 12 months who were treated for acute RSV bronchiolitis [functional oxygen saturation ($SpO_2 \leq 95\%$)] in a pediatric ambulatory clinic in central Israel during the winter seasons of 2009 through 2011. The selection process is shown in figure 1. Inclusion criteria for the study were $SpO_2 \leq 95\%$ [15,18,19] by pulse oximetry (oximeter model 8500; Nonin Medical Inc., Minneapolis, MN) and respiratory rate (RR) > 45 bpm in addition to a score of 9 or more on the Bronchiolitis Caregiver Diary (BCD) [20], a questionnaire of daily bronchiolitis sign and symptoms completed by caregivers of infants with bronchiolitis for rating the severity of episodes of coughing, wheezing, or wheezing with crackles and labored breathing due to respiratory effort, with or without chest recession [9,20,21]. Items are graded on a 6-point scale from 0 (no symptoms or interference) to 5 (very severe symptoms or interference); the maximum score is 20. It has been found to have good interobserver reliability [20]. RSV positivity was confirmed by immunochromatographic assay of nasopharyngeal aspirate (ImmunoCard STAT-RSV, catalog no. 750930; Meridian Bioscience Europe, Villa Cortese, Italy). Infants with chronic diseases (e.g., cardiopulmonary disease, cystic fibrosis, neonatal asthma, malignancy) or immunodeficiency were excluded, as were infants who had received corticosteroids or bronchodilators in any form before presentation and infants whose parents refused to participate or were unable to complete the sign and symptoms BCD. Infants who had recovered from chronic neonatal lung disease of prematurity were included. The study was approved by the ethics (Helsinki) committee of the regional hospital. The parents of all participants provided written informed consent.

Study design

A prospective, randomized, intent-to-treat design was used all participants physician, nurse and parents were blinded to the randomization. Allocation of medication and tanks were concealed prior to randomization. After the parents signed the consent form, patients were randomly assigned to one of three treatment groups (45 patients each), as follows: (1) inhalation therapy with 2 ml of 3% saline followed immediately by 2 l/min oxygen via nasal cannulae for 20 min (‘oxygen hypertonic group’); (2) inhalation therapy with nebulized 0.25 to 0.5 salbutamol diluted in 2 ml of 0.9% saline followed immediately by 2 l/min oxygen via nasal cannulae for 30 min (oxytocin treatment group); (3) inhalation of nebulized 0.25 to 5 ml salbutamol diluted in 2 ml of 0.9% saline (control group + room air filled tanks). Infant under 6 months received 0.25 ml salbutamol, and age 6 to 12 months 0.5 ml. All protocols were administered 4 times daily at 6-hour intervals for 7 consecutive days.

Procedure

On admission day, the enrolling physician EMS measured the baseline $SpO_2$ and RR, while the research nurse recorded the values together with the signs and symptoms score on the BCD and administered the first treatment at the clinic, in accordance with the protocol to which the patient had been assigned. She then supplied the parents with numbered, marked, prefilled bottles and oxygen masks and tank (the control group tank were field with room air) and taught them how to administer the remaining treatments at home. The parents were instructed in standard supportive nasal suction for excess nasal secretions and rehydration, and were given written instructions describing the management of episodes of fever (rectal temperature > 38.4°C; acetaminophen alternating with ibuprofen 0.5 mg/kg/dose every 4 hours, as needed) and signs of a worsening condition: respiratory rate > 65 breaths/minute, oxygen saturation < 85% or cyanosis, BCD score

| Total children available for study (n = 1,732) |
| Total patients with wheezing, crackels, cough, tachypnea, retraction, and chest hyperinflation (n = 743) |
| Total patient diagnosis with clinical bronchiolitis and ($SpO_2 \leq 95\%$) (n = 532) |
| RSV Positive (n = 241) |
| RSV negative (n = 291) and Excluded patients’ |
| Less than 24 months old (n = 233) |
| Less than 12 months of age (n = 218) |
| Eligible and signed consent, and has RR > 45: $SpO_2 \leq 95\%$: Sign and Symptoms ≥ 9 (n = 207) |
| Computer randomization of 145 patient in 3 treatment groups |

Figure 1. Flow of participants throw trial group; (3) inhalation of nebulized 0.25 to 5 ml salbutamol diluted in 2 ml of 0.9% saline (control group + room air filled tanks). Infant under 6 months received 0.25 ml salbutamol, and age 6 to 12 months 0.5 ml. All protocols were administered 4 times daily at 6-hour intervals for 7 consecutive days.

Procedure

On admission day, the enrolling physician EMS measured the baseline $SpO_2$ and RR, while the research nurse recorded the values together with the signs and symptoms score on the BCD and administered the first treatment at the clinic, in accordance with the protocol to which the patient had been assigned. She then supplied the parents with numbered, marked, prefilled bottles and oxygen masks and tank (the control group tank were field with room air) and taught them how to administer the remaining treatments at home. The parents were instructed in standard supportive nasal suction for excess nasal secretions and rehydration, and were given written instructions describing the management of episodes of fever (rectal temperature > 38.4°C; acetaminophen alternating with ibuprofen 0.5 mg/kg/dose every 4 hours, as needed) and signs of a worsening condition: respiratory rate > 65 breaths/minute, oxygen saturation < 85% or cyanosis, BCD score
Sarrell ME (2019) Home oxygen therapy for acute bronchiolitis

Outcome measures

Primary outcome measures of the study were number of emergency department visits and hospitalization admissions within 6 weeks of enrollment. Secondary outcome measures were changes in sign and symptoms BCD score, RR, SpO2, and chest x-ray findings. Tertiary outcome measures were daycare absences by infants, days of work missed by parents, and parental satisfaction with treatment.

Sample size calculation

The success rate for ED referral was estimated at 99%. Using a minimum success rate of 90% of the sample size necessary to detect a difference of half a standard deviation in ED referrals between the oxygen protocols and the control group at a significance level of 1% for two-sided tests with 90% power was calculated according to the formula for binomial proportions for independent samples [24]. The findings showed that we would require 135 infants, 45 in each of the 3 groups.

Statistical analysis

Data were analyzed with the SPSSWIN, version 19. Values were recorded as mean ± SD and median differences in BCD score, RR, SpO2, and parental satisfaction between time points were assessed using analysis of variance (ANOVA) with repeated measures. Differences in mean and median categorical variables among the treatment groups were analyzed by 2-tailed t-test for independent samples; noncontinuous variables (daily changes) were analyzed by chi-square or Friedman test. The Wilcoxon signed-rank test was used to evaluate changes in scores between groups and multiple comparisons was considered between the 3 groups. A 2-tailed p value of 0.05 was used to define statistical significance for differences between groups and to calculate confidence intervals around differences in sample means.

Results

Mean age of the 135 patients at diagnosis of RSV bronchiolitis was 4.7 ± 2.6 months (range 1-12 (95% CI 4.1-6.9) There were no statistically significant differences among the three groups as they were randomly distributed in demographics, home environment, tobacco use at home, neonatal/prenatal complications, or medical history since birth (Table 1). There were also no significant differences among the groups in mean BCD score, RR, or SpO2 at baseline (Table 1 and Figure 2).

During the study, the hospital admission rate was 4.5% in the oxygen hypertonic group and 9.1% in the oxygen salbutamol group compared to 15.1% in the inhalation-only group (p < 0.001). The respective ED self-referral rates were 6.7% and 11.1% compared to 26.8% (p = 0.001) (Table 1). ED referrals and hospitalizations coincided with the appearance of infiltrates on chest x-ray, found at rates of 8.9% in the oxygen hypertonic group and 13.3% in the oxygen salbutamol group compared to 33% in the inhalation-only group (p < 0.0001) (Table 1).

When we analyzed the daily variability in parameter values, we found that BCD sign and symptoms scores dropped to mild (< 4.5) within 4 days in the oxygen hypertonic group (mean score 4.36 ± 1.5, 95% CI 3.9 – 4.81), 6 days in the oxygen salbutamol group (mean score 6.24 ± 1.4, 95% CI 5.83 – 6.66), and 7 days in the inhalation-only group (mean score 7.1 ± 1.9, 95% CI 68 – 7.57), statistically significant in each day and the time it took to reach an acceptable value (p < 0.001) (Figure 2). RR decreased over time, concomitant with an increase in SpO2. In the oxygen hypertonic group, mean RR measured 62.2 ± 18.2 bpm (95% CI 60-64.5) at admission to 31.2 ± 4 bpm (95% CI 30-32.4) on day 2. Corresponding values of SpO2 were 87.2 ± 3.6% (95% CI 86.1- 88.3) and 95.2 ± 1.5% (95% CI 95.1 – 95.8). The oxygen salbutamol group needed 3 days to reach a RR of 34.5 ± 4.3 bpm (95% CI 33.2 – 35.8) and SpO2 of 95.6 ± 1.4% (95% CI 95.1 – 96.1). By contrast, the inhalation-only group needed 7 days to reach an RR of 34.6 ± 5.6 bpm (95% CI 31.7 – 35.4) and, even after 7 days, SpO2 measured only 94.1%. Like for the sign and symptoms BCD score, the differences between each of the oxygen-treated groups and the non-oxygen-treated group were statistically significant (p < 0.001) (Figure 2).

The more rapid clinical improvement in respiratory status in the patients treated with oxygen resulted in significantly fewer missed days of daycare mean 2.18 in the oxygen hypertonic group; 4 in the oxygen salbutamol group, than in the inhalation-only group 5.62 days (p < 0.0001). Accordingly, parents of infants in the oxygen-treated groups lost significantly fewer workdays (mean 2.25 and 3.37, respectively) than in the inhalation-only group (mean 4.5 days) (p < 0.0001) (Table 1).

A satisfaction score above 40 on the 3rd day was recorded by 88% (40.2 ± 1.2) of caregivers in the oxygen hypertonic group, and by 78%
* C* Combing mean score of daytime coughing, wheezing, trouble breathing related to respiratory effort, and nighttime coughing.

NS=Not Significant

**Figure 2.** Median clinical presentation and resolution in the treated groups in relation to control group
Sarrell ME (2019) Home oxygen therapy for acute bronchiolitis

Table 1. Background and clinical characteristics and outcome in infants with bronchiolitis treated with oxygen at home compared to controls

| Outcome | Total No. (n=45) | Hypertonic saline oxygen* | Salbutamol inhalation oxygen** | Salbutamol inhalation only (n=45) |
|---------|------------------|---------------------------|-------------------------------|----------------------------------|
| Pathologic chest X-ray, mean ± SD (CI) (%) | 25 (18.5) | 4 ± (0.5) (2.46-3.03) (8.9%) | 6 ± (1.43) (3.01-4.02) (13.3%) | 15 ± (1.39) (4.75-5.3) (33%) |
| ED referral, mean ± SD (%) | 20.6 (15.2) | 3.2 (6.7%) (±2.6) (±3.5) (1.8-2.4) | 5.3 (11.1%) (±3.5) (±2.6) (2.96-3.48) | 12.1 (26.8) (±2.6) (±1.1) (15.1-17.2) |
| Hospitalized, mean ± SD (CI) (%) | 13.2 (9.7) | 2.3 (4.5%) (±0.3) (±1.8-2.4) | 4.9 ± (1.1) (±0.8) (±3.4-4.02) | 6.8 ± (1.5) (±1.8) (±0.4-1.6) |
| Days missed by child, mean ± SD (CI) | 2.18 ± (0.77) (±2.4) (±3.3) (±1.8) | 4 ± (1.1) (±3.4-4.3) | 5.62 ± (1.2) (±4.75-5.3) | < 0.0001 |
| Parental work absence, Mean ± SD (CI) | 2.25 ± (1.34) (±2.0-2.51) | 3.37 ± (1.3) (±2.9-3.89) | 4.5 ± (1.73) (±3.99-4.62) | < 0.0001 |
| Caregiver satisfaction, Mean (± SD) (%) | 40.2 (88%) (±2.2) (±38.4-41.5) | 35.3 (78%) (±2.7) (±33.7-36.8) | 20.2 (44%) (±0.7) (±19.3-21.2) | < 0.0001 |

(35.3 ± 1.7) of the caregivers in the oxygen salbutamol group. In the inhalation-only group, an acceptable satisfaction score was reported by only 44% (20.2 ± 0.7) of the caregivers (p < 0.0001) (Table 1). Home treatment by the end of the study was preferred by 84% of the caregivers in the oxygen hypertonic group and 73.5% in the + oxygen salbutamol group, compared to 22.2% in the inhalation-only group (p < 0.0001).

Discussion

This study suggests that the administration of oxygen treatment at home in children with uncomplicated RSV bronchiolitis is feasible and safe and can reduce the number of ED referrals and hospital admissions.

The present study assessed a relatively large sample of infants with RSV bronchiolitis, representing the largest and sickest group of children commonly admitted to hospital for treatment [25,26]. Earlier studies found that 57% of children hospitalized for bronchiolitis were younger than 6 months and 81% were younger than 1 year [25]. In our patients, the mean age was 4.7 months; all children were less than one year old. Others noted that the proportion of the one-year age group hospitalized for bronchiolitis increased from 22.2% in 1980 to 47.4% in 1996, commensurate with an increase in total hospitalizations for the same age group from 5.4% to 16.4%, during the same period [25]. The need for oxygen was the major predictor for both hospital admissions and length of stay [27,28]. This finding was supported by Shay et al. [25] that calculated a 2.4-fold increase in hospital admission rates for bronchiolitis in children less than one year old (from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996), was directly related to severity of the illness and SpO2 level.

We speculated that home treatment with oxygen might alleviate at least part of this problem. Our results indicated that home oxygen therapy successfully increased SpO2 and reduced illness severity, thereby lowering the need for hospital admission for oxygen supplementation. Only 6.7% to 11.1% of all the children receiving oxygen visited the ED, of whom 4.5% to 9.1% were admitted. By contrast, among the children receiving standard salbutamol treatment, 26.7% visited the ED and 15.1% were admitted.

With the reduction in ED visits and hospital admissions, ill infants recovered more quickly and returned to daycare activity faster. Caregivers could then return to work earlier, which increased their satisfaction with the treatment and enhanced their trust in the recommendations of the medical staff. We did not directly study the economics of this practice, but earlier studies found that reducing admissions from 22% to 4.5% lowered costs. This is a substantial gain considering that the total annual cost for bronchiolitis-related hospitalizations in the USA in 2002 was $543 million dollars, with a mean of $3,799 dollars per hospitalization [25]. Studies from the United States estimated that the annual hospital costs for bronchiolitis ranged from at $365 to $691 million [4], with an overall cost of treatment of about $2.5 billion per year [1]. Raut et al. [29] calculated a savings of from at $365 to $691 million [4], with an overall cost of treatment of about $2.5 billion per year [1]. Raut et al. [29] calculated a savings of from at $365 to $691 million [4], with an overall cost of treatment of about $2.5 billion per year [1]. Raut et al. [29] calculated a savings of from at $365 to $691 million [4], with an overall cost of treatment of about $2.5 billion per year [1]. Raut et al. [29] calculated a savings of from at $365 to $691 million [4], with an overall cost of treatment of about $2.5 billion per year [1].
saved parents a full workday. Calculated household expenses for a sick child are approximately $538.75 per sick day for a fully employed and insured caregiver and $424.83 if one or more members is unemployed or uninsured [32].

Adjunctive treatment with nebulized bronchodilators remains controversial. Some researchers reported an association of bronchodilator use with improvement in the clinical score compared to placebo but not in measures of oxygenation, rate of hospitalization, or length of hospital stay [33]. Others, however, noted a 9%.

Hartling et al. [34] in a 2004 Cochrane review found insufficient evidence to support the use of bronchodilators for the in-hospital treatment of bronchiolitis. The use of salbutamol in the present study was based on earlier studies. The first showed that nebulized bronchodilators in an outpatient setting appears to lead to more rapid clinical improvement, thereby reducing the burden of care [35]. The second showed that the use of nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis [36], significantly shortened hospital stay and relieved symptoms and signs. These findings were later corroborated by others [37,38]. Most of the infants with mild hypoxia in our area treated in outpatient setting due to lack of hospital availability.

The rate of pathologic findings on chest radiographs in the present study was 20% in the inhalation-only group, 12.6% in the salbutamol oxygen group, and 9.3% in the hypertonic oxygen group. The finding in the latter group is in agreement with the study of Farah et al. [39] in which infiltration was noted in 17% of chest radiographs taken in children less than 12 months old with a first episode of wheezing during the RSV season.

The present study was limited by its small size, due to funding and operational constraints. Other limitations were short duration (7 days) and lack of data on repeated-dose pharmacokinetics, biological safety, and effect of prolonged use of the combined treatment. The short duration could also have reduced the statistical power to detect adverse events. Furthermore, randomization was not stratified by illness severity, so it is possible that one group contained more infants with severe illness than the others. It is also noteworthy that the results cannot be extrapolated to children aged more than 12 months or children with malnutrition, chronic illnesses, compromised immune function, congenital heart disease, or reinfection with RSV. We are also aware that the referrals to the ED and subsequent hospital admissions may have been affected by parental anxiety. We believe that some of the infants would not have been referred had the decision been left solely to the primary care physician.

In conclusion, home-administered oxygen treatment combined with bronchodilator or 3% hypertonic solution to carefully selected infants with mild to moderate acute bronchiolitis appears to improve clinical symptoms and the rate of chest complications, thereby reducing the rate of referrals to the ED and hospital admissions. Children return to daycare earlier and parental absenteeism from work is reduced. Intense primary care supervision is required for good results. Further in-depth studies in larger and more varied populations are needed to confirm these findings.

References
1. Leader S, Kohlase K (2003) Recent trends in severe respiratory syncytial virus (RVS) among US infants, 1997 to 2000. J Pediatr 143: S127-S132. [Crossref]
2. Fitzgerald DA, Kiham HA (2004) Bronchiolitis: assessment and evidence-based management. Med J Aust 180: 399-404. [Crossref]
28. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, et al. (2009) Epinephrine and dexamethasone in children with bronchiolitis. *N Engl J Med* 360: 2079-2089. [Crossref]

29. Raut M, Schein J, Mody S, Grant R, Benson C, et al. (2009) Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the U.S. *Curr Med Res Opin* 25: 2151-2157. [Crossref]

30. Subcommittee on Diagnosis and Management of Bronchiolitis (2006) Diagnosis and Management of Bronchiolitis. Pediatrics 118: 1774-93. [Crossref]

31. Li S, Leader S (2007) Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the U.S. *Respir Med* 101: 1244-50. [Crossref]

32. Deshpande SA, Northern V (2003) The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. *Arch Dis Child* 88: 1065-1069. [Crossref]

33. Kellner JD, Ohlsson A, Gadomski AM, Wang EE (1999) Bronchodilators for bronchiolitis. *Cochrane Database Syst Rev* 1: CD001266. [Crossref]

34. Hartling L, Wiebe N, Russell K (2004) Epinephrine for bronchiolitis. *Cochrane Database Syst Rev* 1: CD003123. [Crossref]

35. Sarrell EM, Meyerovich J (2010) Epinephrine and bromhexine in the ambulatory treatment of bronchiolitis. *J Ped Infec Dis* 122: 2015-2020. [Crossref]

36. Sarrell EM, Tal G, Witzling M (2002) Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. *Chest* 122: 2015-2020. [Crossref]

37. Villanueva P, Standish J, Douglas K, Mensah F, Jachno K, et al. (2011) Efficacy of hypertonic nebulized saline in bronchiolitis: Improved outcome measures needed. *J Pediatr* 159: 353. [Crossref]

38. Luo Z, Fu Z, Liu E, Xu X, Fu X, et al. (2010) A randomized controlled trial of nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis. *Clin Microbiol Infect* 17: 1829-1833 [Crossref]

39. Farah MM, Padgett LB, McLario DJ, Sullivan KM, Simon HK (2002) First-time wheezing in infants during respiratory syncytial virus season: chest radiograph findings. *Pediat Emerg Care* 18: 333-336. [Crossref]